|
1
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Makkouk A and Weiner GJ: Cancer
immunotherapy and breaking immune tolerance: New approaches to an
old challenge. Cancer Res. 75:5–10. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chia WK, Teo M, Wang WW, Lee B, Ang SF,
Tai WM, Chee CL, Ng J, Kan R, Lim WT, et al: Adoptive T-cell
transfer and chemotherapy in the first-line treatment of metastatic
and/or locally recurrent nasopharyngeal carcinoma. Mol Ther.
22:132–139. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jin CG, Chen XQ, Li J, Wu ZP, Liu X and
Wang XC: Moderating effects and maintenance of lung cancer cellular
immune functions by CIK cell therapy. Asian Pac J Cancer Prev.
14:3587–3592. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mesiano G, Todorovic M, Gammaitoni L,
Leuci V, Giraudo Diego L, Carnevale-Schianca F, Fagioli F,
Piacibello W, Aglietta M and Sangiolo D: Cytokine-induced killer
(CIK) cells as feasible and effective adoptive immunotherapy for
the treatment of solid tumors. Expert Opin Biol Ther. 12:673–684.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kelly RJ: Immunotherapy for esophageal and
gastric cancer. Am Soc Clin Oncol Educ Book. 37:292–300. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zou WP and Chen LP: Inhibitory B7-family
molecules in the tumour microenvironment. Nat Rev Immunol.
8:467–477. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brahmer JR, Drake CG, Wollner I, Powderly
JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller
TL, et al: Phase I study of single-agent anti-programmed death-1
(MDX-1106) in refractory solid tumors: Safety, clinical activity,
pharmacodynamics, and immunologic correlates. J Clin Oncol.
28:3167–3175. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chung HC, Arkenau HT, Wyrwicz L, Oh DY,
Lee KW, Infante JR, Chin KM, von Heydebreck A, Kang YK and Safran
H: Safety, PD-L1 expression, and clinical activity of avelumab
(MSB0010718C), an anti-PD-L1 antibody, in patients with advanced
gastric or gastroesophageal junction cancer. J Clin Oncol. 34 4
suppl:S1672016. View Article : Google Scholar
|
|
10
|
Hamid O, Robert C, Daud A, Hodi FS, Hwu
WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al:
Safety and tumor responses with lambrolizumab (anti-PD-1) in
melanoma. N Engl J Med. 369:134–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Topalian SL, Sznol M, McDermott DF, Kluger
HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB,
Powderly JD, et al: Survival, durable tumor remission, and
long-term safety in patients with advanced melanoma receiving
nivolumab. J Clin Oncol. 32:1020–1030. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wolchok JD, Kluger H, Callahan MK, Postow
MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K,
et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J
Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hofmann L, Forschner A, Loquai C,
Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal
JS, Göppner D, et al: Cutaneous, gastrointestinal, hepatic,
endocrine, and renal side-effects of anti-PD-1 therapy. Eur J
Cancer. 60:190–209. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Helissey C, Vicier C and Champiat S: The
development of immunotherapy in older adults: New treatments, new
toxicities? J Geriatr Oncol. 7:325–333. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cousin S and Italiano A: Molecular
pathways: Immune checkpoint antibodies and their toxicities. Clin
Cancer Res. 22:4550–4555. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Selenko-Gebauer N, Majdic O, Szekeres A,
Höfler G, Guthann E, Korthäuer U, Zlabinger G, Steinberger P, Pickl
WF, Stockinger H, et al: B7-H1 (programmed death-1 ligand) on
dendritic cells is involved in the induction and maintenance of T
cell anergy. J Immunol. 170:3637–3644. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Atefi M, Avramis E, Lassen A, Wong DJ,
Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, et
al: Effects of MAPK and PI3K pathways on PD-L1 expression in
melanoma. Clin Cancer Res. 20:3446–3457. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Okazaki T and Honjo T: PD-1 and PD-1
ligands: From discovery to clinical application. Int Immunol.
19:813–824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Palucka K and Banchereau J: Cancer
immunotherapy via dendritic cells. Nat Rev Cancer. 12:265–277.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hargadon KM: Strategies to improve the
efficacy of dendritic cell-based immunotherapy for melanoma. Front
Immunol. 8:15942017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tähtinen S, Grönberg-Vähä-Koskela S, Lumen
D, Merisalo-Soikkeli M, Siurala M, Airaksinen AJ, Vähä-Koskela M
and Hemminki A: Adenovirus improves the efficacy of adoptive T-cell
therapy by recruiting immune cells to and promoting their activity
at the tumor. Cancer Immunol Res. 3:915–925. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cavalcanti A, Santos R, Mesquita Z, Duarte
AL and Lucena-Silva N: Cytokine profile in childhood-onset systemic
lupus erythematosus: A cross-sectional and longitudinal study. Braz
J Med Biol Res. 50:e57382017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yan Y, Li S, Jia T, Du X, Xu Y, Zhao Y, Li
L, Liang K, Liang W, Sun H and Li R: Combined therapy with CTL
cells and oncolytic adenovirus expressing IL-15-induced enhanced
antitumor activity. Tumour Biol. 36:4535–4543. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ray A, Das DS, Song Y, Richardson P,
Munshi NC, Chauhan D and Anderson KC: Targeting PD1-PDL1 immune
checkpoint in plasmacytoid dendritic cell interactions with T
cells, natural killer cells and multiple myeloma cells. Leukemia.
29:1441–1444. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang J, Riella LV, Chock S, Liu T, Zhao X,
Yuan X, Paterson AM, Watanabe T, Vanguri V, Yagita H, et al: The
novel costimulatory programmed death ligand 1/B7.1 pathway is
functional in inhibiting alloimmune responses in vivo. J Immunol.
187:1113–1119. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Curiel TJ, Wei S, Dong HD, Alvarez X,
Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann
MC, et al: Blockade of B7-H1 improves myeloid dendritic
cell-mediated antitumor immunity. Nat Med. 9:562–567. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ueno H, Schmitt N, Klechevsky E,
Pedroza-Gonzalez A, Matsui T, Zurawski G, Oh S, Fay J, Pascual V,
Banchereau J and Palucka K: Harnessing human dendritic cell subsets
for medicine. Immunol Rev. 234:199–212. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Volovitz I, Melzer S, Amar S, Bocsi J,
Bloch M, Efroni S, Ram Z and Tárnok A: Dendritic cells in the
context of human tumors: Biology and experimental tools. Int Rev
Immunol. 35:116–135. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
MacDonald KP, Munster DJ, Clark GJ,
Dzionek A, Schmitz J and Hart DN: Characterization of human blood
dendritic cell subsets. Blood. 100:4512–4520. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Trinchieri G: Interleukin-12 and the
regulation of innate resistance and adaptive immunity. Nat Rev
Immunol. 3:133–146. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vogt A, Sievers E, Lukacs-Kornek V, Decker
G, Raskopf E, Meumann N, Büning H, Sauerbruch T, Strassburg CP,
Schmidt-Wolf IG and Gonzalez-Carmona MA: Improving immunotherapy of
hepatocellular carcinoma (HCC) using dendritic cells (DC)
engineered to express IL-12 in vivo. Liver Int. 34:447–461. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Legitimo A, Consolini R, Failli A, Orsini
G and Spisni R: Dendritic cell defects in the colorectal cancer.
Hum Vacc Immunother. 10:3224–3235. 2014. View Article : Google Scholar
|
|
33
|
Huang J, Tatsumi T, Pizzoferrato E,
Vujanovic N and Storkus WJ: Nitric oxide sensitizes tumor cells to
dendritic cell-mediated apoptosis, uptake, and cross-presentation.
Cancer Res. 65:8461–8470. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu S, Yu Y, Zhang M, Wang W and Cao X:
The involvement of TNF-alpha-related apoptosis-inducing ligand in
the enhanced cytotoxicity of IFN-beta-stimulated human dendritic
cells to tumor cells. J Immunol. 166:5407–5415. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Blankenstein T: The role of tumor stroma
in the interaction between tumor and immune system. Curr Opin
Immunol. 17:180–186. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Butler MO, Lee JS, Ansén S, Neuberg D,
Hodi FS, Murray AP, Drury L, Berezovskaya A, Mulligan RC, Nadler LM
and Hirano N: Long-lived antitumor CD8+ lymphocytes for adoptive
therapy generated using an artificial antigen-presenting cell. Clin
Cancer Res. 13:1857–1867. 2007. View Article : Google Scholar : PubMed/NCBI
|
